Cite
MLA Citation
Ana Oaknin et al.. “Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study.” Journal for immunotherapy of cancer, vol. 10, no. 1, 2022, p. . http://access.bl.uk/ark:/81055/vdc_100150408289.0x00000d